Ignite Creation Date:
2024-05-06 @ 8:40 AM
Last Modification Date:
2024-10-26 @ 12:03 PM
Study NCT ID:
NCT02797964
Status:
COMPLETED
Last Update Posted:
2023-06-18
First Post:
2016-05-23
Brief Title:
A Phase 12 Trial of SRA737 in Subjects With Advanced Cancer
Sponsor:
Sierra Oncology LLC - a GSK company
Organization:
Sierra Oncology LLC - a GSK company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Solid Tumors or Non-Hodgkins Lymphoma NHL |
Keywords:
| Name | View |
|---|---|
| Genetic biomarkers | View |
| Replication stress | View |
| Advanced solid tumors | View |
| CCNE1 | View |
| TP53 | View |
| BRCA1 | View |
| BRCA2 | View |
| MYC | View |
| RAD50 | View |
| Fanconi anemia | View |
| Cell cycle | View |
| Metastatic Colorectal Cancer | View |
| Platinum-Resistant or Intolerant High Grade Serious Ovarian Cancer | View |
| Advanced Non-Small Cell Lung Cancer | View |
| Metastatic Castration-Resistant Prostate Cancer | View |
| Head and Neck Squamous Cell Carcinoma | View |
| Squamous Cell Carcinoma of the Anus | View |
| Phase 1 | View |
| Phase 2 | View |
| Dose escalation | View |
| Chk1 inhibitor | View |
| Checkpoint kinase 1 | View |
| Synthetic lethality | View |
| Next-Generation Sequencing | View |